South Korea's regulatory authority has amended data requirements for the designation of orphan drugs for rare and life-threatening diseases

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1423, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

South Korea's regulatory authority has amended data requirements for the designation of orphan drugs for rare and life-threatening diseases

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 446, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Indian local prices for drugs to treat life-threatening diseases, such as HIV/AIDS, cancer and heart disease, could rise by as much as 10-20 times above their current rates

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 470, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

By Simoens Steven  

Drugs & Therapy Perspectives, Vol. 27, Iss. 10, 2011-10 ,pp. : 24-26

Adis International

Access to resources Recommend Favorite

Orphan Drugs for Rare Diseases: Is it Time to Revisit Their Special Market Access Status?

By Simoens Steven  

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1437-1443

Adis International

Access to resources Recommend Favorite

Rationing of Drugs for Rare Diseases

By Hughes Dyfrig  

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 315-316

Adis International

Access to resources Recommend Favorite